OKUR
NASDAQOnKure Therapeutics Inc.
News25/Ratings3
Price$3.80-0.41 (-9.74%)
2026-05-222026-08-26
News · 26 weeks53+100%
2026-03-012026-08-23
Mix2890d
- Insider20(71%)
- SEC Filings5(18%)
- Other3(11%)
Latest news
25 items- INSIDERAmendment: SEC Form 4 filed by Director Manke Isaac4/A - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Andrew John4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Manke Isaac4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Jansen Valerie Malyvanh4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Grey Michael G4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Carruthers R Michael4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Saccomano Nicholas A4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Leverone Jason A.4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Hartley Dylan4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Agresta Samuel4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form 424B5 filed by OnKure Therapeutics Inc.424B5 - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form 10-Q filed by OnKure Therapeutics Inc.10-Q - OnKure Therapeutics, Inc. (0001637715) (Filer)
- PROnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Hosted a Key Opinion Leader event highlighting the evolving PI3Kα treatment landscape and the scientific rationale supporting OnKure's next-generation PI3Kα pan-mutant inhibitor programs -- Participated as an exhibitor and sponsor at the ISSVA World Congress 2026 in Philadelphia, supporting engagement with leading vascular anomalies clinicians and researchers -- $176 million of cash, cash equivalents and marketable securities expected to fund operations into 2029 BOULDER, Colo., Aug. 04, 202
- PROnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company's structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, click here. Management will provide an overview of OnKure’s strategy for de
- INSIDERPresident and CEO Saccomano Nicholas A sold $378 worth of shares (86 units at $4.40), decreasing direct ownership by 0.76% to 11,247 units (SEC Form 4) (for tax liability)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERChief Financial Officer Leverone Jason A. sold $1,332 worth of shares (303 units at $4.40), decreasing direct ownership by 2% to 18,802 units (SEC Form 4) (for tax liability)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Andrew John4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Jansen Valerie Malyvanh4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Grey Michael G4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
OKUR FAQ
6 questionsWhere does OKUR stock trade?
OnKure Therapeutics Inc. (OKUR) is listed on NASDAQ.What sector and industry is OKUR in?
OnKure Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did OnKure Therapeutics Inc. go public?
OnKure Therapeutics Inc. (OKUR) completed its IPO in 2021.What are analysts saying about OKUR?
OnKure Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2025-04-30. Recent price targets range from $3300.00 to $3500.00.What companies are similar to OKUR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OKUR side-by-side with any of them on Quantisnow.How can I track OKUR on Quantisnow?
Quantisnow aggregates OnKure Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKUR to receive live email and push alerts on every new disclosure.